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StatinThepresentmodelling studyaimedtoevaluate if andbyhowmuch functional foods containingphytosterols/-stanols
add to the beneﬁts of statins in the prevention of cardiovascular disease in terms of cost-effectiveness. Long-term
health effects, measured as quality-adjusted life-years gained, and costs for scenarios with additional
phytosterol/-stanol use were compared to scenarios without extra use. Phytosterols/-stanols were given only
to persons who were eligible for use according to their 10-year absolute risk of fatal cardiovascular disease
(SCORE-risk). Intake levels and discontinuation rates as observed in daily practice were included in the model.
Two situations were compared: 1) A real-life situation in which persons at high SCORE-risk were identiﬁed
through clinical case-ﬁnding and, 2) A theoretical maximum situation where universal screening was
implemented resulting in known SCORE-risks for the whole Dutch population aged 35–75 years (8.4 million
people). Sensitivity analyses were performed for variations in the cholesterol-lowering effect and intake level of
phytosterols/-stanols, indirect health care costs, time horizon and discount rates. At the model's start year, a
total of 1.0 (real-life situation) to 3.3 (maximum situation) million persons qualiﬁed for phytosterol/-stanol
use based on their SCORE-risk (both statin users and statin non-users). Over the model's time horizon, this
resulted in a gain of 2700 to 16,300 quality-adjusted life-years, and yielded cost-effectiveness ratios that
ranged between €92,000 and €203,000 per quality-adjusted life-year. This simulation study showed that the
cost-effectiveness of phytosterols/-stanols as monotherapy and as add-on to statins is above thresholds for
cost-effectiveness, generally ranging between €20,000 and €50,000, and is thus a non-cost-effective
strategy to reduce cardiovascular disease.B Utrecht, The Netherlands. Tel.: +31 30 253 7324; fa
Cathy.Rompelberg@rivm.nl (C.J.M. Rompelberg).
.: +31 30 274 2387; fax: +31 30 274 4466.
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Despite the steady decline in death rates fromcardiovascular disease
during the last decades, cardiovascular disease continues to be one of
the biggest health care problems in terms of burden of disease and
health care costs (http://www.who.int/en/). The beneﬁcial effects of
statins in the primary and secondary prevention of cardiovascular
disease arewell established (Baigent et al., 2005;Heart Protection Study
Collaborative Group, 2002). These beneﬁts are primarily attributed to
the lipid-lowering properties of statins: it has been estimated that
statins reduce low-density-lipoprotein (LDL)-cholesterol levels by
18–55% (Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults, 2002; Jones et al., 2003; Law et al.,
2003). In addition to this cholesterol-lowering activity, statins
possess multiple pleiotropic effects (Ray and Cannon, 2005; Ray
and Cannon, 2007). In Europe, current recommendations for
cardiovascular risk management are based on the Systematic
COronary Risk Evaluation (SCORE)-risk charts (Conroy et al., 2003;
De Backer et al., 2003). In 2006, for The Netherlands an adapted
SCORE-risk chart has been developed using national data (Dutch
Institute for Healthcare Improvement and Dutch College of General
Practitioners, 2006). From the charts, the 10-year absolute risk of
fatal cardiovascular disease can be derived, taking into account
several risk factors (gender, age, smoking, systolic blood pressure,
and serum total cholesterol or total/HDL-cholesterol ratio). Accord-
ing to the Dutch guidelines, treatment with a statin in the primary
prevention of cardiovascular disease is recommended for all persons
with a 10-year SCORE-risk of fatal cardiovascular disease ≥10%,
unless LDL-cholesterol is less than 2.5 mmol/l. For subjects with type
2 diabetes mellitus or established cardiovascular disease, treatment
is recommended for all persons with LDL-cholesterol≥2.5 mmol/l.
The use of functional foods enriched with phytosterols and
phytostanols is an alternative strategy to lower elevated total and
LDL-cholesterol levels. Phytostanol- and phytosterol-enriched mar-Table 1
Overview of scenarios in the real-life and theoretical maximum situation.
Situation Scenario Phytoster
Real-life (RL)
RL reference Real-life (No chang
RL plus PS (min) Minimum real-life plus PS By all cur
RL plus PS (max) Maximum real-life plus PS By all cur
subjects w
Theoretical maximum (TM)
TM reference Maximum statin use (No chang
TM plus PS Maximum statin and PS use By all cur
with a 10
PS, Phytosterols/-stanols.garines were launched on the Dutch market in 1999 and 2000,
respectively and its use has increased in the past years in both users
and non-users of statins (Eussen et al., unpublished data). In a recent
meta-analysis, Demonty et al. (2009) found that a daily dose of 2.15 g
phytosterols/-stanols reduces LDL-cholesterol by 8.8%. Furthermore,
phytosterols and -stanols seem to be equally effective in both statin
users and statin non-users (Eussen et al., 2010a). It is generally
assumed that phytosterols/-stanols will decrease coronary heart
disease by lowering cholesterol levels, although there are no studies
yet to conﬁrm this (Katan et al., 2003). The guidelines for
cardiovascular risk management recommend that all persons with a
10-year SCORE-risk ≥5% should be given lifestyle recommendations,
including the encouragement of the use of phytosterols/-stanols as
part of a healthy diet (Dutch Institute for Healthcare Improvement
and Dutch College of General Practitioners, 2006; Law, 2000).
There is currently no universal screening for risk factors of
cardiovascular disease in The Netherlands, nor in any other EU
country. Consequently, the detection of high cholesterol values and
other cardiovascular disease risk factors occurs primarily through
clinical case-ﬁnding. As a result many people are unaware that they
are at high risk for cardiovascular disease and could beneﬁt from
statin and/or phytosterol/-stanol use (Mantel-Teeuwisse et al., 2003).
The aging of the population togetherwith the risinghealth care costs
requires considering the cost-effectiveness and budgetary impact of
different intervention strategies. In cost-effectiveness analyses the costs
and health effects of an intervention are compared to determine
whether the intervention provides value-for-money (Morris et al.,
2007). Statins have been assessed for cost-effectiveness in a range of
publications (for review see Franco et al. (2005) and Gumbs et al.
(2007)), and were found to be cost-effective for high risk patients
(Franco et al., 2005; Ward et al., 2007). In contrast, to date only two
studies evaluated the cost-effectiveness of phytosterols or -stanols
(Gerber et al., 2006; Martikainen et al., 2007). In both studies it was
concluded that phytosterols and -stanols are (potentially) cost-effectiveol/-stanol use Statin use
e in phytosterol/-stanol use) (No change in statin use)
rent real-life statin users (No change in statin use)
rent real-life statin users and all
ith a 10-year SCORE-risk ≥5%, b10%
(No change in statin use)
e in phytosterol/-stanol use) By all subjects with a 10-year SCORE-risk
≥10%
rent real-life statin users and all subjects
-year SCORE-risk ≥5%
By all subjects with a 10-year SCORE-risk
≥10%
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amount of 2 g phytosterols/-stanols (without discontinuation). How-
ever, neither study included an economic evaluation in which real-life
consumption patterns of phytosterols/-stanolswere taken into account,
nor were all health beneﬁts and costs considered. Moreover, the
incremental costs and health effects of phytosterols/-stanols in addition
to statins have not been evaluated.
Therefore, the present study aimed to evaluate the health beneﬁts,
i.e. the prevention of cardiovascular disease, and health care costs of
functional foods enriched with phytosterols/-stanols in addition to
statin therapy, taking into account the intake levels and discontinu-
ation rates as observed in daily practice.
2. Methods
The cost-effectiveness of the use of functional foods with
phytosterols/-stanols as monotherapy and as add-on to statin therapy
was estimated both in a real-life situation, i.e. passive clinical case-
ﬁnding to identify subjects eligible for treatment with statins, and in a
theoretical maximum situation, i.e. assuming that free population-
based screening is implemented resulting in known 10-year SCORE-
risks for thewholeDutchpopulationbetween35 and75 years of age and
all subjects with a SCORE-risk ≥10% are treated with statins. This
theoretical situation gives information about the maximum health
beneﬁts that can be achieved with phytosterols/-stanols in addition to
optimal statin therapy.
In both the real-life and theoretical maximum situation, long-term
disease prevalence and mortality rates, as well as health care resource
use, were simulated and compared for two scenarios using the RIVM
Chronic Disease Model (Section 2.2). The ﬁrst scenario is the current
situation in which functional foods enriched with phytosterols/-stanols
are used as customary in the Dutch population. A large part of the
populationdoes not use phytosterols/-stanols,whereas others use them
on their own initiative or on general practitioner's advice. In the second
scenario an increase in phytosterol/-stanol use is considered, both as a
monotherapy for subjects with a modestly elevated risk (SCORE-risk
≥5%, b10%), and as add-on to statin therapy for subjects with a highly
elevated risk (SCORE-risk ≥10%) (Table 1).
2.1. Scenarios
2.1.1. Real-life (RL) situation
In a clinical case-ﬁnding or real-life situation the SCORE-risk is
only known for subjects who have their cholesterol level and blood
pressure assessed, presumably the ones that are susceptible to a high
risk of cardiovascular events and/or health-conscious people.
2.1.1.1. RL reference: real-life situation with customary phytosterol/-stanol
use. The RL reference scenario assumed no additional phytosterol/-stanol
use in a real-life situation. It reﬂects the real-life consumption patterns of
phytosterols/-stanols, including actual daily intake levels and discontin-
uation rates (Sections 2.3.2 and 2.3.3). In this scenario population
numbers, morbidity rates and health care costs of the Dutch population
that was between 35 and 75 years of age in 2007 were simulated over a
time horizon of 50 years. Data from the population-based Doetinchem
Cohort Study were used to estimate subjects' 10-year SCORE-risk and
current phytosterol/-stanol use in the Dutch population (Verschuren
et al., 2008). In this ongoing cohort study, participants are examined in
consecutive 5-year intervals. The most recent data were used for the
current study, collected during the years 2003–2007, which included
about 4500 persons. Current statin and combined users of both statins
and phytosterols/-stanols were identiﬁed by linking the data of each
participant of the Doetinchem Cohort Study to their pharmacy-
dispensing records using the Pharmacomorbidity-Record Linkage
System (http://www.pharmo.nl/) (Eussen et al., 2010b).2.1.1.2. RL plus PS: real-life situation with additional phytosterol/-stanol
use. In the RL plus PS scenario subjects who have a known SCORE-risk
≥5% were assumed to start phytosterol/-stanol use. We assumed that
in the Dutch population all current statin users had their SCORE-risk
assessed at the beginning of their therapy and their SCORE-risk was
≥10%, conforming to the guidelines. These subjects start using
phytosterols/-stanols. In addition, we assumed that subjects with a
known modestly elevated risk (SCORE-risk ≥5, b10%) start using
phytosterols/-stanols. However, in a real-life setting it is difﬁcult to
identify which fraction of the Dutch population has their SCORE-risks
assessed and no general practitioners' data were available onwhich to
make a reliable estimate. Therefore, we deﬁned a minimum and
maximum scenario for phytosterol/-stanol use. In the minimum real-
life plus phytosterols/-stanols scenario (RL plus PS (min)), only current
statin users start using phytosterols/-stanols, which results in a
minimum number of additional phytosterol/-stanol users. In the
maximum real-life plus phytosterols/-stanols scenario (RL plus PS
(max)), both current statin users and all subjects with a SCORE-risk
≥5, b10% start using phytosterols/-stanols, resulting in a maximum
number of additional phytosterol/-stanol users (Table 1). The true
number of additional phytosterol/-stanol users in the general
population lies somewhere between these two extremes.
The cost-effectiveness of additional phytosterol/-stanol use in a
real-life situation was obtained by subtracting the results of the
real-life scenario (RL reference) from the scenarios with added
phytosterols/-stanols (RL plus PS (min) and RL plus PS (max)).
2.1.2. Theoretical maximum (TM) situation
In the theoretical maximum situation it is assumed that the
SCORE-risk for the whole Dutch population aged between 35 and
75 years is known. In this situation, all subjects with a 10-year SCORE-
risk ≥10% start using statins in both scenarios. Subjects already using
statins before the start of the scenario were assumed to continue
taking their current medication.
2.1.2.1. TM reference: maximum situation with customary phytosterol/
-stanol use. The TM reference scenario assumed customary use of
phytosterols/-stanols in a situation with maximum statin use. It
reﬂects the real-life consumption patterns of phytosterols/-stanols,
including actual daily intake levels and discontinuation rates
(Sections 2.3.2 and 2.3.3).
2.1.2.2. TM plus PS: maximum situation with additional phytosterol/-stanol
use. In this scenario, we assumed phytosterol/-stanol use in all subjects
with a 10-year SCORE-risk ≥5% and combined use of phytosterols/
-stanols and statins in all subjects with a 10-year SCORE-risk ≥10%.
Because all current statin users supposedly have or had a SCORE-risk
≥10%, they were also assumed to start using phytosterols/-stanols
(Table 1).
The cost-effectiveness of additional phytosterol/-stanol use in the
maximum situation was obtained by subtracting the results of the
scenario without added phytosterols/-stanols (TM reference) from the
scenario with added phytosterols/-stanols (TM plus PS).
2.2. The Chronic Disease Model
The RIVM Chronic Disease Model is a Markov-type, dynamic
population-based model developed at the National Institute for Public
Health and the Environment (RIVM) with the purpose to evaluate
effects of public health policy on the incidence and prevalence of
chronic diseases in the Dutch population (Hoogenveen et al., 2008;
Hoogenveen et al., 2010; van Baal et al., 2005). The model links
lifestyle and lifestyle related risk factors to morbidity and mortality
using relative risks for disease incidence. It contains data on smoking,
alcohol, cholesterol levels, blood pressure and food intake, as well as
data on 13 chronic diseases (van Baal et al., 2005). For the current































Fig. 1. The modelling of cholesterol in relation to cardiovascular disease in the Chronic
Disease Model. In the Chronic Disease Model the model population is stratiﬁed into
eight classes of cardiovascular risk, based on total cholesterol levels (TC) and the use of
statins (upper part of ﬁgure). After a change in cholesterol level, subjects may either
transit to another cholesterol class ( ) or remain in the same cholesterol class ( ).
After initiating statin therapy, subjects transit from one of the right four classes (‘Statin
non-user’) to one of the left four classes (‘Statin user’). Subjects in all classes are at risk
of cardiovascular disease, with different classes having different risks of developing
cardiovascular disease (lower part of ﬁgure). The model includes different relative risk
estimates for chronic heart failure (CHF), stroke and acute myocardial infarction (AMI),
and accounts for interactions between these diseases. Subjects are always of risk of
death from cardiovascular disease-related and other-cause mortality. This risk depends
on the class the subject belongs to.
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disease is especially important. The Chronic Disease Model includes
different relative risk estimates for acute myocardial infarction,
stroke, and chronic heart failure, and accounts for interactions
between these diseases, with for instance myocardial infarction
increasing the risk of chronic heart failure (Fig. 1). For an example
of a recent application of the model in the evaluation of nutritional
effects on the risk of cardiovascular disease see Engelfriet et al. (2010).
The Chronic Disease Model simulates effects on health and costs
over the model's time horizon for a model population, accounting for
a background rate of new phytosterol/-stanol and statin users and
background changes in cholesterol level (e.g., due to aging) over time.
The model population was stratiﬁed into four classes based on total
cholesterol level, with cut-off values of 5.0, 6.5 and 8.0 mmol/l. Each
class was further subdivided into two groups based on the use of
statins (yes/no), resulting in eight different classes of cardiovascular
risk. The incidence of cardiovascular disease is increased for higher
classes of total cholesterol and absence of statin use (due to the
pleiotropic effects of statins), and also, e.g., with higher age and male
gender. Transitions between the classes are possible, reﬂecting
starting or stopping the use of statins, and changes in total cholesterol
level, e.g. due to increased phytosterol/-stanol use in our scenarios
(Fig. 1).
2.3. Model input data
2.3.1. General demographic data and data on risk factors and diseases
General demographic data on total mortality, birth rates and
population size were obtained from Statistics Netherlands
(http://statline.cbs.nl/statweb/). Age- and sex-speciﬁc initial preva-
lences of risk factors, including cholesterol levels, and transitions
between risk factor classes were obtained from large representative
DutchHealthmonitoring studies (Hofmanet al., 1995;Houterman et al.,
2001; Verschuren et al., 2008; Westert et al., 2005). Finally, data on
disease speciﬁc prevalence, incidence, remission and mortality were
obtained from four general practitioners' registrations (Donker, 2010;
Engelfriet et al., 2011; Verheij et al., 2009; Verheij et al., 2010; Westert
et al., 2005).
2.3.2. Intake and effect of phytosterols/-stanols and statins
The average per person daily intake of phytosterols/-stanols in the
scenarios with additional phytosterol/-stanol use was derived from the
averages assessed in the Doetinchem Cohort Study by a food frequency
questionnaire. The questionnaire contained an open question on the
brand name of bread spread used (e.g. phytosterol/-stanol-enriched
bread spreads) and photographs of 4 differently sized portions. The
average intake level was 1.05 g phytosterols/-stanols per day. This
intake level would cause a reduction in total cholesterol of 4.7% (95%
CI: −7.2 to −3.2) based on the dose–response relation in the meta-
analysis by Demonty et al. (2009) (Appendix A).
The use of different types and dosages of statins in The
Netherlands in 2009 was derived from the GIP-databank, a drug
information system of the Dutch Health Care Insurance Board
(http://www.gipdatabank.nl/), containing reimbursement data on
almost the whole Dutch population. The average hypocholesterolemic
effect of these different statins was estimated to be 24.6% (Illingworth
and Tobert, 1994; Maron et al., 2000; Penning-van Beest et al., 2007)
(Appendix A).
It was assumed that statins and phytosterols/-stanols had additive
cholesterol-lowering effects, i.e. 29.3%, when used in combination
(Eussen et al., 2010a; Neil et al., 2001; Simons, 2002).
2.3.3. Discontinuation of phytosterols/-stanols and statins
In daily life, many subjects discontinue the use of phytosterols/
-stanols and/or statins (Luoto et al., 2004; Mantel-Teeuwisse et al.,
2004). Suffering from side effects such as myalgia, for example, isconsidered a reason for stopping statin therapy (Bates et al., 2009). To
adapt our scenarios to this daily life experience, we have included
discontinuation rates fornewusers of phytosterol/-stanol andnewstatin
users. For phytosterols/-stanols these were estimated from the percent-
age of subjects who stopped the use of phytosterols/-stanols between
subsequent rounds in the Doetinchem Cohort Study. We assumed that
subjectswhodiscontinuedphytosterols/-stanols, stopped in theﬁrst and
second year with discontinuation rates of 33% after one year and 44%
after two years. Subjects who adhere to the use of phytosterols/-stanols
for at least two years, were assumed to continue use during the rest of
their lives. In subjectswho discontinued theuseof phytosterols/-stanols,
the total cholesterol level was assumed to return to the same level as
before the start of the scenario.
Discontinuation rates for statins were 38.5% after one year and
53.5% after two years (Mantel-Teeuwisse et al., 2004). As for
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to the same level as before the start of the scenario in subjects who
discontinued statin therapy. New combined users of statins and
phytosterols/-stanols were assumed to stop both with a probability as
if they were statin only users.
2.3.4. Health effects
Health effects were computed in terms of quality-adjusted life-
years, a measure of the life expectancy of a person (in years) adjusted
for the quality of life (Gold et al., 2002), by using data from the Global
and Dutch Burden of Disease studies (Lopez and Murray, 1998; Melse
et al., 2000; Stouthard et al., 2000; van Baal et al., 2005; van Baal et al.,
2006). Total quality-adjusted life-years lived by the model population
in each year of the simulation were found by tracking population sizes
and disease prevalence. Net present values of quality-adjusted life-
years were calculated by adding annual quality-adjusted life-years
over the model's time horizon of 50 years, discounting future quality-
adjusted life-years at 1.5% according to Dutch guidelines for
pharmacoeconomic research (College voor Zorgverzekeringen,
2006). Similarly, net present values of life-years saved were obtained.
2.3.5. Intervention costs and health care costs
We have calculated all intervention costs as well as both directly
and indirectly related health care costs. Costs are expressed in Euros
and are based on Dutch unit prices of 2010. Future costs were
discounted at 4% annually according to the Dutch guidelines (College
voor Zorgverzekeringen, 2006).
Intervention costs included all costs related to the intervention, i.e.
costs related to phytosterols/-stanols and, additionally for the
theoretical maximum situation, all costs related to statin use. With
respect to intervention costs for phytosterols/-stanols, we assumed
that phytosterols/-stanols were incorporated into a bread spread. The
additional costs of using the phytosterol/-stanol-enriched margarine
instead of regular bread spread without phytosterols/-stanols was
estimated at €6.20/kg (€9.68/kg for enriched margarine minus €3.48/
kg for regular margarine) which amounts to €31.68/yr for current
phytosterol/-stanol intake levels (1.05 g phytosterols/-stanols per day
equals 5.1 kg margarine per year). In addition, we assumed that all
phytosterol/-stanol users had one doctor visit (€24,80) (Nederlandse
Zorgautoriteit, 2009) and one lipid test (€24,98) (Nederlandse
Zorgautoriteit, 2010) every 5 years costing in total €10,-/yr. Annual
statin drug costs were estimated at €150/yr, based on the distribution of
the different types and dosages of statin use in The Netherlands and theTable 2
The number of phytosterol/-stanol (PS) users and the effect of additional phytosterol/-stan
theoretical maximum (TM) situation, cumulative over the 50-year period of the simulation (
Costs were discounted at 4%, and life-years and quality-adjusted life-years at 1.5%. Data for
Real-life (RL)
Effect of additiona
RL reference RL plus PS (min)
No. of subjectsa (×1000) 8407 +0
No. of PS usersa (×1000) 615 +1048






Health care (direct and indirect)b 895,800 +29
Total 895,800 +502
Cost-effectiveness (€ per QALY gained)
Intervention costs 192,200
Total costs 203,000
PS, Phytosterols/-stanols; QALY, Quality-adjusted life-years.
a At onset of scenario.
b Direct costs include all future savings related to diseases averted by using PS and/or stacorresponding costs (http://www.gipdatabank.nl/). Statin users were
assumed to have one doctor visit, one lipid test (Dutch Institute for
Healthcare Improvement and Dutch College of General Practitioners,
2006) and three repeat prescriptions every year (€12.40 each)
(Nederlandse Zorgautoriteit, 2009), summing up to a total of €237,-/yr.
Health care costs included future savings related to diseases averted
by using phytosterols/-stanols and/or statins and those resulting from
surviving longer (indirect health care costs) (van Baal et al., 2007).
Lifetime health care costs were calculated in the Chronic Disease Model
based on disease prevalence combinedwith age and gender speciﬁc data
from the Dutch Cost of Illness Study (http://www.kostenvanziekten.nl/)
(Poos et al., 2005; van Baal et al., 2005; van Baal et al., 2008).
2.4. Calculation of cost-effectiveness
Cost-effectiveness ratios were calculated by dividing incremental
costs (Euros) by health beneﬁts (quality-adjusted life-years) gained
due to the additional use of phytosterols/-stanols. First, intervention
costs per quality-adjusted life-year gained were computed and second,
total costs per quality-adjusted life-year gained, i.e. intervention costs
plus all differences in health care costs. These cost-effectiveness ratios
represent the value-for-money provided by adding treatment with
phytosterols/-stanols to current statin use (real-life situation) aswell as
to maximal statin use resulting from screening (maximum situation).
2.5. Uncertainty and sensitivity analysis
Probabilistic uncertainty analysis was used to evaluate the
combined effect of uncertainty regarding the effectiveness of
phytosterols/-stanols and the use of the Doetinchem Cohort data to
estimate the cholesterol levels in the Dutch population. For this
uncertainty analysis, Monte Carlo simulation was used, with 100
independent simulations drawing for each simulation new parame-
ter-values for the dose–response curve from their 95% conﬁdence
interval (CI). Each simulation used a new distribution over the eight
cholesterol classes, assuming Dirichlet distributions for the conver-
sion of the cholesterol distribution of the Doetichem Cohort to the
Dutch population.
A series of univariate sensitivity analyses were performed to
evaluate the impact of other important model assumptions and
parameters on the results. The daily phytosterol/-stanol intake
amount was set at the recommended level of 2 g/day. We assumed
this was obtained by an increased concentration in bread spread atol use on health effects, costs, and the cost-effectiveness ratios in the real-life (RL) and
as compared to the reference scenario for each situation, RL reference and TM reference).
the Dutch population aged 35–75 years (8.4 million people).
Theoretical maximum (TM)
l PS use Effect of additional PS use













































RL plus PS (min) RL plus PS (max) TM plus PS
Fig. 2. Effect of additional phytosterol/-stanol (PS) use on discounted (1.5%) quality-
adjusted life-years (QALYs) gained per year in the real-life (RL) and theoretical
maximum (TM) situation. Data are expressed as extra QALYs gained compared to the
reference scenario for each situation (RL reference and TM reference).
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were set to zero and indirectly related health care costs were
disregarded. Furthermore, discount rates on costs and effects of 0%,
3% and 5% were used, and a discount rate of 4% for costs combined
with 0% for effects. Finally, time horizons of 10, 20 and 30 years were
evaluated.
3. Results
3.1. Number of phytosterol/-stanol and statin users
At the start of the simulation (year 2007), about 615,000 members
(7%) of the Dutch population aged between 35 and 75 years used




















































































RL plus PS (min) RL plus PS (max) TM plus PS
B
Fig. 3. Effect of additional phytosterol/-stanol (PS) use on discounted (4%) annual
intervention costs (A) and health care costs (B) in the real-life (RL) and theoretical
maximum (TM) situation. Data are expressed as extra costs compared to the reference
scenario for each situation (RL reference and TM reference).scenarios (RL reference and TM reference) (Table 2). Statins were used
by approximately 1.2 million (14%) and 1.5 million (18%) persons in
the real-life and theoretical maximum situation, respectively.
Due to the implementation of the scenarios the number of
phytosterol/-stanol users increased. The number of extra phytosterol/
-stanol users in a real-life situation ranged between 1.0 million (RL plus
PS (min)) and2.6million (RLplus PS (max)). In the theoreticalmaximum
situation, a total of 3.3 million subjects started phytosterol/-stanol use
(TM plus PS).
3.2. Health effects
For both the real-life and theoretical maximum situation, the
discounted total health effects at the end of the simulation (after
50 years), expressed as life-years and quality-adjusted life-years
gained, in the scenarios with additional phytosterol/-stanol use as
compared to the reference scenarios (RL reference and TM reference)
are shown in Table 2. In the real-life situation, a total of 3600 life-years
or 2700 quality-adjusted life-years (on average 0.0034 life-year or
0.0026 quality-adjusted life-year per extra phytosterol/-stanol user)
were gained if all current statin users would start the use of
phytosterols/-stanols (RL plus PS (min)). A total of 15,500 life-years
or 12,400 quality-adjusted life-years (on average 0.0060 life-year or
0.0048 quality-adjusted life-year per extra phytosterol/-stanol user)
were gained when additionally also all subjects with a modestly
elevated risk (≥5, b10%) would start using phytosterols/-stanols
(RL plus PS (max)). Additional phytosterol/-stanol use in the
theoretical maximum situation resulted in a total of 16,300 quality-
adjusted life-years (19,500 life-years) gained, or 0.0049 quality-
adjusted life-year (0.0059 life-year) per extra phytosterol/-stanol
user (TM plus PS). Fig. 2 shows the discounted extra quality-adjusted
life-years gained per year by additional phytosterol/-stanol use
compared to the reference scenario for each situation (RL reference
or TM reference). In both situations, the quality-adjusted life-years
gained by extra phytosterol/-stanol use reached a maximum after
some 20 years when most people in the cohort are old but still alive,
and some cardiovascular events can be delayed or prevented by the
use of phytosterols/-stanols. Further in time, more and more people
die and fewer events can be prevented.
3.3. Intervention costs and health care costs
The effect of additional phytosterol/-stanol use on cumulative
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Fig. 4. Cost-effectiveness of additional phytosterol/-stanol (PS) use in the real-life (RL)
and theoretical maximum (TM) situation. Costs and quality-adjusted life-years (QALYs)
are expressed as extra total costs and extra QALYs gained, cumulative for the years
2007–2057 (as compared to the reference scenario for each situation, RL reference and
TM reference). The symbols are the cost-effectiveness ratio of each model run in the
uncertainty analysis (100 runs in total). The lines represent cost-effectiveness ratios of
€20,000, €50,000 and €80,000.
Table 3
Results for cost-effectiveness ratio of the uncertainty and sensitivity analyses. The inﬂuence of changes in effectiveness and intake level of phytosterols/-stanols, discontinuation,
discount rates and time horizon on the cost-effectiveness ratio (total extra costs per quality-adjusted life-year gained) of additional phytosterol/-stanol use in the real-life (RL) and
theoretical maximum (TM) situation (as compared to the reference scenarios). Data are cumulative over the 50-year period of the simulation.
Real-life (RL) Theoretical maximum (TM)
RL plus PS (min) RL plus PS (max) TM plus PS
Variable Values Cost-effectiveness ratio (€ per QALY gained)a
Reference 203,000 96,400 92,200
Effectiveness of PS on reducing TCb Lower bound of 95% CI (−3.2%) 349,300 171,700 151,800
Upper bound of 95% CI (−7.2%) 134,400 69,700 63,200
PS intakec (g/day) 2 168,600 78,800 86,400
Discontinuationd (%) 0 193,600 101,100 121,500
Indirect health care costs 0 210,500 96,700 88,100
Discount ratese (%) 0, 0 334,000 155,300 122,300
3, 3 348,300 174,000 145,500
5, 5 368,300 191,400 165,300
4, 0 177,100 83,400 65,600
Time horizon (years) 10 589,900 330,500 374,000
20 335,200 155,500 167,100
30 238,200 123,000 123,400
PS, Phytosterols/-stanols; QALY, Quality-adjusted life-years. TC, total cholesterol.
a Cost-effectiveness ratio is expressed as extra costs per extra quality-adjusted life-year gained compared to costs and quality-adjusted life-years of the reference scenario for each
situation (RL reference and TM reference).
b Combined effect of uncertainty regarding the effectiveness of PS (Appendix A) and the use of the Doetinchem Cohort data to estimate the cholesterol levels in the Dutch
population.
c Intake of PS was increased without additional costs.
d Discontinuation rates for both PS and statins.
e Discount rates for costs and effects, respectively.
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costs were about a factor 10 higher than health care costs, and ranged
between €0.47 billion for added phytosterols/-stanols in the minimum
real-life situation (RL plus PS (min)) to €1.26 billion for added
phytosterols/-stanols in the theoretical maximum situation (TM plus
PS). Intervention costs were the highest at the beginning of the
simulation, declined steadily during the ﬁrst two years due to
discontinuation of phytosterol/-stanol and statin use, and gradually
reached zeronear the endof the simulationwhenmost of the cohort has
died (Fig. 3a). Fig. 3b shows the difference in discounted health care
costs per year in the scenarios with additional phytosterol/-stanol use
compared to the reference scenarios (RL reference or TM reference).
Apart from minor savings in health care costs during the ﬁrst three
years, health care costs were higher with additional phytosterol/-stanol
use than without the additional use. This can be explained by the fact
that subjects with a healthier cholesterol level live longer. During their
longer lifetime they develop more diseases, with associated costs (van
Baal et al., 2007). The costs of these indirectly related health effects turn
out to be higher than the prevented costs of cardiovascular events.
Consequently, the more people that start using phytosterols/-stanols,
the higher the health care costs.
3.4. Cost-effectiveness
Mean incremental total costs per quality-adjusted life-year for
additional phytosterol/-stanol use varied between €96,000 and
€203,000 in the real-life situation, and were about €92,000 in the
theoretical maximum situation (Table 2). When only the costs of the
intervention itself were considered, mean costs were approximately
€10,000 lowerper quality-adjusted life-year, resulting inmean costs per
quality-adjusted life-year between €84,000 and €192,000. Fig. 4 shows
the cost-effectiveness of additional phytosterol/-stanol use for the
different scenarios. The cost-effectiveness ratios were compared to
threshold values of €20,000, €50,000 and €80,000 per additional
quality-adjusted life-year (Boersma et al., 2010; van Gils et al., 2010).
In themaximum real-life situation (RL plus PS (max)) and themaximum
situation (TM plus PS), the addition of phytosterols/-stanols had a
probability between 30% and 44% of being cost-effective at a threshold
value of €80,000. When a threshold for cost-effectiveness of €20,000 or€50,000 was considered, the addition of phytosterols/-stanols was not
cost-effective in any of the 100 uncertainty simulation runs, neither in
the real-life situation, nor in the theoretical maximum situation.
3.5. Uncertainty and sensitivity analyses
Results of the uncertainty and sensitivity analyses are shown in
Table 3. As expected, an increase in effectiveness of phytosterols/-stanols
(total cholesterol reduction increased from4.7% to 7.2%, the upper bound
of the 95% CI) and an increased intake of phytosterols/-stanols (from
1.05 g/day to the recommended levels of 2 g/day) resulted in more
favourable cost-effectiveness ratios. Assuming no discontinuation of
phytosterols/-stanols or statins did only marginally affect the cost-
effectiveness ratio. Apparently, lifetime health beneﬁts of the phytos-
terols/-stanols seem to be counterbalanced by the lifetime payment for
phytosterols/-stanols. Disregarding indirect health care costs did not
change the results, due to the fact that health care costs (both direct and
indirect)were only 10%of the total costs. Considering a greater difference
in discount rates for costs and effects, i.e. a higher discount rate for costs
and a lower rate for effects, resulted in a more favourable cost-
effectiveness ratio, explained by the fact that the costs of the intervention
are largelymade in theﬁrst years,whereas a longer time-span is required
to achieve effects of the intervention. Shorter time horizons led to a less
cost-effective intervention, becausemuch intervention costs aremade at
the start, whereas most of the health gains appear later.
4. Discussion
The present study suggests that the use of functional foods
enriched with phytosterols/-stanols as monotherapy and as add-on to
statin therapy is a non-cost-effective strategy to reduce cardiovascular
disease. In a situation in which persons eligible for use were identiﬁed
through passive clinical case-ﬁnding, the cost-effectiveness of
phytosterols/-stanols ranged from about €96,000 to €203,000 per
quality-adjusted life-year. A slightly lower (more favourable) cost-
effectiveness ratio of €92,000 was obtained when subjects qualifying
for phytosterols/-stanols were found through a (hypothetical)
universal screening program for cardiovascular disease (costs of the
universal screening program were not included in the analyses). In
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threshold values for cost-per-quality-adjusted life-year, which gen-
erally range between €20,000 and €50,000 (Boersma et al., 2010; van
Gils et al., 2010). These threshold values for cost-effectiveness ratios
were also not reached in sensitivity analyses in which treatment effect
or intake level of phytosterols/-stanols was increased, or future health
care costs were not taken into account.
This is the ﬁrst study evaluating whether functional foods enriched
withphytosterols/-stanols are a cost-effective strategy in addition to the
beneﬁcial effects of statins in the prevention of cardiovascular disease.
Two studies have been performed to assess the cost-effectiveness of
phytosterols/-stanols alone (Gerber et al., 2006; Martikainen et al.,
2007). Gerber et al. (Gerber et al., 2006) found that €52 per person could
be saved when phytosterol/-stanol-enriched margarine was consumed
by the entire German population between 30 and 79 years of age. In
contrast to our study Gerber et al. disregarded intervention costs, i.e.
costs of the functional foods enriched with phytosterols/-stanols and
costs for doctor visits and lipid tests. Martikainen et al. (Martikainen et
al., 2007) found cost-effectiveness ratios between €7436 and €112,151,
conditional on age and gender, and concluded that phytosterol/-stanol-
enriched functional foods were a cost-effective option for high-risk
persons (adult men and women aged 60 years or older). One of the
reasons for the difference between the results of these two studies and
the present one is that, although phytosterols/-stanols are recom-
mended for subjects with elevated cholesterol levels (Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults, 2002; Clifton, 2009) or elevated SCORE-risks (Dutch Institute for
Healthcare Improvement and Dutch College of General Practitioners,
2006; Law, 2000), all persons in a certain age group were treated with
phytosterols/-stanols in the previous studies, regardless of a person's
cholesterol level or SCORE-risk (Gerber et al., 2006; Martikainen et al.,
2007). Moreover, both previous studies assumed perfect adherence to
phytosterols/-stanols, i.e. the continuous use of the recommended daily
amount of 2 g phytosterols or -stanols. Actual adherence is, however,
known to be less than optimal (Luoto et al., 2004; Wolfs et al., 2006).
People do stop the use of phytosterols/-stanols and consume less than
the recommended intake amount. Finally, neither previous study
considered costs caused by diseases other than cardiovascular disease,
acquired later in the life-years saved. Yet, it is more and more
recommended that these indirectly related health care costs should be
included in economic evaluations (van Baal et al., 2007; Feenstra et al.,
2008; Nyman, 2004; Meltzer, 2008). Nevertheless, with respect to the
latter two aspects, sensitivity analyses which disregarded discontinu-
ation of phytosterols/-stanols or indirect health care costs did not
substantially alter the results.
We assumed that phytosterols/-stanols were incorporated into a
bread spread. Although enriched bread spreads are the most
commonly used source for phytosterols/-stanols today, the market
is expanding to include other dairy products, like yoghurt (drinks)
and milk. Nevertheless, costs (in Euros 2010) for recommended daily
intake levels of enriched yoghurt drinks and milk are €0.60 and €1.05,
respectively, which is notably higher than costs for recommended
intake levels of the bread spread (€0.25). Consequently, this would
result in even more unfavourable cost-effectiveness ratios.
In the present study, the cost-effectiveness of phytosterols/-stanols
was evaluated both in a real-life situation and in a theoretical maximum
situation. In themaximum situation, persons eligible for statin treatment
or lifestylemodiﬁcations (phytosterols/-stanols)were selected following
the Dutch guidelines for cardiovascular risk management. However, it is
known that not all general practitioners follow these guidelines and use
the SCORE risk calculation charts that accompany the guidelines (Hobbs
and Erhardt, 2002; Scheltens et al., 2009). Besides general practitioner-
related factors, also patient-related factors may have contributed to the
fact that in the present study, one ﬁfth (n=321,000) of the subjects
eligible for statin use were not using them. Patients may refrain from
starting statin therapy, or may discontinue the medication because ofside effects or lackof effect (Finnet al., 2009). In addition, a fewdeviations
between the guidelines and the implementation of the guidelines in our
scenarios should be mentioned. Firstly, the guidelines offer separate
recommendations for subjects with and subjects without type 2
diabetes mellitus or established cardiovascular disease. In the current
analysis, all patients suffering from type 2 diabetes or cardiovascular
disease were considered to have the same probability of receiving
phytosterols/-stanols and statins as the general population. Thus, we
underestimated the chance of being treated for these patients.
Furthermore, the guidelines consider subjects with a 10-year SCORE-
risk of fatal cardiovascular disease ≥10% eligible for statin treatment,
unless their LDL-cholesterol level is b2.5 mmol/l. We were not able to
include this limitation as in the Doetinchem Cohort Study, which was
assumed to represent the Dutch population, only subjects' total and
HDL-cholesterol level was assessed. However, under the assumption
that 80%of the circulating cholesterol in thehumanbody is bound to LDL
(Crowley, 2009), less than1% of theDutch populationwith a SCORE-risk
≥10%has a LDL-cholesterol level below2.5 mmol/l. Thiswouldnot have
affected the estimated cost-effectiveness of phytosterols/-stanols.
We have used the Chronic Disease Model to project future effects on
health and health care costs. Some limitations of the use of this model
need to be addressed. Most importantly, continuous risk factors, such as
total cholesterol level, in the Chronic Disease Model are categorized into
four classes (Fig. 1). As a consequence, subjects already in the lowest
cholesterol risk factor class before the start of the simulation cannot gain
beneﬁts from the phytosterols/-stanols. This may result in an underes-
timation of the effects of phytosterols/-stanols. Nonetheless, there is
currently no evidence that lowering total cholesterol levels below the
established target values of 5 mmol/l is associated with lower mortality
(Jacobson, 2000; Warren, 2008). Moreover, estimates of relative risks of
cardiovascular disease in the Chronic DiseaseModel are based on studies
from different countries. Although this results in the best approximation
of the available data, it is unknownwhether this approach gives the best
values for the Dutch relative risk estimate. Finally, in using the Chronic
Disease Model, some assumptions had to be made. Firstly, it was
assumed that the association between cholesterol-lowering effects of
phytosterols/-stanols and reduction in cardiovascular disease was
similar to the associations seen for other cholesterol-lowering
strategies and cardiovascular disease risk reduction. Secondly, we
assumed that subjects entering the model were similar to those
enrolled in the Doetinchem Cohort Study with respect to SCORE-risk
and phytosterol/-stanol and statin use. However, the Doetinchem
Cohort is not entirely representative for the Dutch population. Smokers
and the lower educated appear to be underrepresented in the cohort
(Verschuren et al., 2008). Since smoking is associated with increased
total cholesterol levels (Craig et al., 1989) and phytosterol/-stanol-
enriched margarines are less often used by the lower educated (Eussen
et al., 2011), SCORE-risks and the percentage of phytosterol/-stanol-
and statin-users in the Dutch population are likely to be slightly
different than those estimated from the Doetinchem Cohort Study.
In conclusion, this simulation study shows that the intake of
functional foods enriched with phytosterols/-stanols for those with
elevated cardiovascular disease risk, as encouraged in the guidelines
for cardiovascular risk management, is above Dutch and international
thresholds for cost-effectiveness, and is thus a non-cost-effective
strategy to reduce cardiovascular disease. This study demonstrates
the importance of incorporating cost-effectiveness assessments in
health care resource allocation decision-making. Comparing the cost-
effectiveness of phytosterol/-stanol-enriched functional foods to
other (functional) foods and drugs is suggested to be a critical step
in assessing their broader applicability.
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Appendix A
Calculation of total cholesterol-lowering effect of phytosterols/-stanols
Predicted LDL-cholesterol change (%) =−a⋅ 1−exp − doseb = ln 2ð Þ
  
(Demonty et al., 2009), where a is−12.68% (95% CI:−15.38 to−9.99)
and b is 1.12 g/day (95% CI: 0.62 to 1.63).
The average daily intake level of phytosterols/-stanols, estimated
from the food frequency questionnaire used in the DoetinchemCohort
Study, was 1.05 g phytosterols/-stanols per user. From the distribu-
tions in a and b 10,000 random drawings were taken, resulting in a
predicted LDL-cholesterol change of−5.85% (95%CI:−8.94 to−4.03).
Under the assumptions that the cholesterol-lowering effect of
phytosterols/-stanols only affects LDL-cholesterol and that 80% of
the circulating cholesterol in bound to LDL (Crowley, 2009), this
results in a predicted total cholesterol reduction of 4.7% (95% CI:−7.2
to−3.2).
Calculation of total cholesterol-lowering effect of statins
Estimated reductions in total cholesterol resulting from the deﬁned
daily dose (DDD), i.e. the averagemaintenancedose per day for a drug in
adults (World Health Organization (WHO) Collaborating Centre for
DrugStatisticsMethodology, 2010),were taken fromPenning-vanBeest
et al. (Penning-van Beest et al., 2007) (Supplemental Table 1).
Information about the number of users of various types of statins and
theDDDconsumed in TheNetherlandswas taken fromtheGIPdatabank
(http://www.gipdatabank.nl/). Subsequently, the reduction in total
cholesterol resulting from the average consumed dose was calculated
per type of statin (Supplemental Table 2).
The average reduction in total cholesterol of all different types and
doses of statins that were consumed was calculated by multiplying
the percentages of the various statins used by the reduction in total
cholesterol at the consumed dose, and was found to be 24.6%.
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